Condition: Myasthenia Gravis, Generalized · Sponsor: Aurinia Pharmaceuticals Inc.
This clinical study will enroll patients with generalized myasthenia gravis (gMG). The goal of this clinical study is to assess the safety, tolerability, effectiveness, pharmacokinetics (how the body processes the drug) and pharmacodynamics (how the drug affects the body) of aritinercept.
This description comes directly from the study's public registry record.
Aurinia Clinical Trials Information · 833-606-5975 · clinicaltrials@auriniapharma.com
Always discuss trial participation with your own doctor first.
| Aurinia Investigational Site | Altamonte Springs, Florida, United States | Recruiting |
| Aurinia Investigational Site | Boca Raton, Florida, United States | Recruiting |
| Aurinia Investigational Site | Miami, Florida, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07596901